Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02768870
Other study ID # HMCE-1002-00k
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 28, 2016
Est. completion date September 6, 2022

Study information

Verified date January 2024
Source Edwards Lifesciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and performance of the Harpoon Medical device. It is anticipated, that the Harpoon Medical device will provide advantages over current surgical interventions including: 1) a small minimally invasive incision, 2) no sternotomy, 3) no cardiopulmonary bypass, 4) no aortic manipulation, 5) a direct path to the valve plane, 6) performed on a beating heart, 7) real-time TOE-guided chordal length adjustment and 8) less complicated procedure that is teachable and adoptable.


Description:

The device is designed to reduce the degree of mitral regurgitation by delivering and anchoring artificial chordae tendineae to the affected mitral valve leaflet(s) in a beating heart.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date September 6, 2022
Est. primary completion date November 6, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Patient referred for mitral valve surgery - Presence of severe MR as read on an echocardiographic study performed within 60 days prior to procedure - Estimated post-ePTFE chordae tendineae implantation coaptation surface is adequate in the judgment of the operating surgeon and the patient eligibility committee - Degenerative mitral valve disease - Patient is able to sign informed consent and able to return for follow-up and is capable of participating in all testing associated with this clinical investigation - Women of child-bearing potential have a negative pregnancy test Exclusion Criteria: - Age < 18 years - Infective endocarditis - Anterior or bileaflet prolapse - Functional MR - History of Mediastinal Radiation - Inflammatory (rheumatic) valve disease - Requirement for concomitant cardiac surgery (e.g., coronary artery bypass grafting (CABG), aortic valve surgery, etc.) - Symptomatic coronary artery disease - Cardiogenic shock at the time of enrollment - ST segment elevation myocardial infarction requiring intervention within 30 days prior to enrollment - Evidence of cirrhosis or hepatic synthetic failure - Pregnancy at the time of enrollment (women of child bearing age should have negative pregnancy within 14 days of surgery) - Severe pulmonary hypertension (PA systolic pressure > 70 mmHg) - Previous cardiac surgery, or surgery on the left pleural space - Left ventricular, atrial or appendage thrombus - Severely calcified mitral leaflets - Recent stroke (< 6 months) with permanent impairment - EuroScore (for mitral valve repair) > 8% - Patients with contraindications to Transoesophageal echocardiography - Severe left or right ventricular dysfunction - NYHA Class IV - Renal insufficiency CKD stage 3b or worse (GFR < 45 ml/min/1.73 m2) - Patient is participating in another clinical study for which follow-up is currently ongoing. (Co-enrollment in an investigational device or interventional study) - Patient with non-cardiac co-morbidities and life expectancy < 1 year - Patient has a condition or conditions that, in the opinion of the Investigator, preclude participation, including willingness to comply with all follow-up procedures

Study Design


Intervention

Device:
Harpoon Artificial ePTFE Chords
It is anticipated that use of the Harpoon device could achieve similar outcomes to open cardiac surgery while decreasing the invasiveness of mitral valve repair.

Locations

Country Name City State
Italy Ospedale San Raffaele Hospital Milan
Italy University Hospital Padova Padova
United Kingdom The Royal Brompton and Harefield NHS Foundation Trust London
United Kingdom University Hospital Southampton NHS Trust Southampton

Sponsors (1)

Lead Sponsor Collaborator
Edwards Lifesciences

Countries where clinical trial is conducted

Italy,  United Kingdom, 

References & Publications (1)

Gammie JS, Bartus K, Gackowski A, D'Ambra MN, Szymanski P, Bilewska A, Kusmierczyk M, Kapelak B, Rzucidlo-Resil J, Moat N, Duncan A, Yadev R, Livesey S, Diprose P, Gerosa G, D'Onofrio A, Pitterello D, Denti P, La Canna G, De Bonis M, Alfieri O, Hung J, Ko — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Subject's Procedural Success During the First 30 Days Procedural success was defined as the patient leaving the operating room with a successful implant of one or more ePTFE cords on the mitral valve and reduced mitral regurgitation from severe to End of procedure through 30 days
Primary Percentage of Subject's With Freedom From Serious Adverse Events (SAE) </= 30 Days Subject's freedom from Serious Adverse Events during the ePTFE implantation procedure and at 30 days follow-up. Time to events were estimated by Kaplan-Meier method. Procedure and 30 days
Primary Subject's Serious Adverse Events (SAE) Through Discharge Number of Participants experiencing a Serious Adverse Event (SAE) through time of Discharge. Discharge, an average of 5 days post implant
Secondary Subject's Severity of Mitral Regurgitation Over Time Valvular regurgitation occurs when the valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation. The numbers on the scale are reflected as follows: 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak.
Higher numbers on the scale show a worsening outcome.
6 months, 12 months, 18 months, 24 months, 30 months, and 36 months
Secondary Percentage of Subject's With Freedom From Serious Adverse Events (SAE) Post-implant > 30 Days Subject's freedom from Serious Adverse Events at >30 days post-implant. Time to events were estimated by Kaplan-Meier method. 6 months, 12 months, 18 months, 24 months, 30 months, and 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT03962023 - Prognostic Impact of Imaging Parameters in Patients With Primary Mitral Insufficiency by Prolapse (COHORTE-IM)
Withdrawn NCT02624960 - Safety and Performance of the AccuCinch® System N/A
Terminated NCT02428010 - Twelve Transcatheter Mitral Valve Replacement (TMVR) Pilot Study N/A
Active, not recruiting NCT01533883 - Cardioband Adjustable Annuloplasty System for Minimally Invasive Mitral Valve Repair N/A
Unknown status NCT01201070 - Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery Phase 4
Terminated NCT00700947 - Using Beta Blockers to Treat Mitral Regurgitation Phase 1
Completed NCT04351984 - Transcatheter Mitral Valvuloplasty Pilot Study
Completed NCT04231331 - Ertugliflozin for Functional Mitral Regurgitation Phase 3
Completed NCT05742789 - Effect of Anesthetics on Troponin I and ะก-reactive Protein Phase 1
Recruiting NCT02803957 - Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair N/A
Recruiting NCT04153292 - The ENCIRCLE Trial N/A
Completed NCT02607527 - Annular Reshaping of the Mitral Valve for Patients With Mitral Regurgitation Using the Millipede IRIS System N/A
Active, not recruiting NCT03066050 - Long Term Follow Up for CTSN Mitral Valve Repair Studies
Active, not recruiting NCT04443218 - Edwards PASCAL Transcatheter Valve Repair System Registry
Enrolling by invitation NCT04067635 - Primary Mitral Regurgitation Repair
Completed NCT01966146 - Examination of Valve Insufficiency Before and After MitraClip or TAVI Procedure by 3D Echocardiography Compared to MRI N/A
Recruiting NCT01368575 - Surgical Treatment of Ischemic Mitral Regurgitation Phase 4
Completed NCT00001314 - Investigation of Heart Function in Patients With Heart Valve Defects N/A
Terminated NCT03285724 - Safety and Performance Study of the Harpoon Mitral Valve Repair System N/A
Withdrawn NCT04709042 - Acquisition of Objective Data During Transapical Neochordae Implantation N/A